These findings suggest that the ability of cabozantinib to promote ferroptotic cytotoxicity in NSCLC cells is mechanistically linked to its suppression of the STAT3/MCL1 signaling axis, a property not shared by the other VEGFR TKIs tested. This evidence concerns the gene MCL1 and non-small cell lung carcinoma.